Mutational Landscape of Patients with Wiskott Aldrich Syndrome: Update from India
- PMID: 39688652
- DOI: 10.1007/s10875-024-01848-w
Mutational Landscape of Patients with Wiskott Aldrich Syndrome: Update from India
Abstract
Purpose: Wiskott-Aldrich syndrome (WAS) is an X-linked genetic disorder characterized by distinctive features including microthrombocytopenia, eczema and recurrent infections. In the present study we report clinical, immunological and molecular spectrum of 41 WAS patients diagnosed over last five years.
Methods: Clinical and family history was collected from case records. Comprehensive immunological assessments including lymphocyte subset analysis, and flow cytometry based evaluation of WAS protein (WASP) expressions were performed in patients along with evaluation of carrier status in mothers. Genetic analysis was carried out with either Sanger sequencing or targeted exome sequencing.
Results: The patients included in this study presented at a median age of 9.5 months, with two adult cases. Clinical manifestations encompassed thrombocytopenia, eczema, bleeding, diarrhea, respiratory tract infections, CMV infection, and malignancy. Immunological phenotype revealed T cell lymphopenia, B cell lymphopenia, and elevated IgE levels. Flow cytometry analysis of WASP was performed in 36 cases out of which 68.42% demonstrated complete absent expression while others showed reduced expression. Genetic analysis highlighted that the majority of mutations affect the WH1 domain of WASP while both adult patients showed intronic mutations. Molecular Dynamics analysis conducted for the novel variants P398R and G33R showed an average RMSD (Å) higher than that of the wild type, indicating greater structural perturbations in WASP.
Conclusion: In the present study we have documented 56.09% novel WAS mutations in Indian cohort. Notably, the application of flow cytometry has emerged as a valuable and efficient diagnostic tool for identifying these WAS patients.
Keywords: Clinical immunology; Cohort study; Inborn errors of immunity; Wiskott Aldrich Syndrome.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Ethical Approval: This study has been approved by Institutional Ethics committee (IEC)-National Institute of Immunohaematology (ICMR) Mumbai (Ref: NIIH/IEC/11-2016). Consent to Participate: We have received written informed consent from the patient's guardians. Consent for Publication: Informed consent has been signed by the guardians for publishing this data. Conflict of Interest: The authors declare that there are no conflicts of interest to disclose.
References
-
- Ochs HD, Filipovich AH, Veys P, Cowan MJ, Kapoor N. Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol Blood Marrow Transplant. 2009;15(1 Suppl):84–90. https://doi.org/10.1016/j.bbmt.2008.10.007 . - DOI - PubMed
-
- Wada T, Itoh M, Maeba H, Toma T, Niida Y, Saikawa Y, Yachie A. Intermittent X-linked thrombocytopenia with a novel WAS gene mutation. Pediatr Blood Cancer. 2014;61(4):746–8. https://doi.org/10.1002/pbc.24787 . - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
